Gapping up
In reaction to strong earnings/guidance/SSS:
In reaction to strong earnings/guidance/SSS:
- LE +19.1%, SCVL +16.1%, MEI +8.7%, BVXV +2.3%, TD +1.4%, COST +1.3%, (Aug comps), WDAY +0.9%, PAHC +0.7%, FRED +0.7%, (Aug comps), LEJU+0.6%
M&A news:
- BKS +4.8% (Hearing strength attributed to renewed M&A speculation)
- YUME +1.7% (RhythmOne said to be near a deal to acquire YuMe for $185 mln in cash and stock, according to SkyNews)
Other news:
- NXTD +20% (says its FitPay subsidiary is powering the payment capabilities for the vívoactive 3, a new smartwatch by Garmin International (GRMN))
- OTIC +7% (modest rebound after closing 80%+ lower y'day)
- APRI +6.3% (notified by the FDA that it has acknowledged receipt of its recently resubmitted NDA for Vitaros and considers it a complete, class 2 response to the Company's 2008 action lette)
- VVUS +4.4% (Vivus enters into a settlement agreement with Dr. Reddy's (RDY) resolving patent litigation related to Qsymia)
- OTEX +2.8% (files mixed securities shelf offering )
- APEN +2.6% ( announces CE Mark approval for the ORBERA365 Managed Weight Loss System)
- AN +2% (continued strength)
- EXPE +1.1% (confirms CFO Mark Okerstrom to succeed Dara Khosrowshahi as CEO; Khosrowshahi to remain on Expedia board)
- MRCY +0.9% (Mercury received Aerospace Standard 9100 certification for its Mercury Defense Systems Advanced Design Centers)
- AZN +0.8% (Phase III PACIFIC data reinforce potential of Imfinzi)
Analyst comments:
- YY +4.5% (initiated with Buy at Goldman)
- MOMO +4.1% (initiated with Buy at Goldman)
- PTEN +1.9% (initiated with a Buy at Societe Generale)
- FCAU +1.6% (target raised to $30.10 from $22.40 at Goldman)